Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Of all the climate challenges to afflict Australia, drought is one of the most feared, and costly. Major droughts, such as that of 1982–83, and the Millennium drought of 1997–2010 can have a ...